Assessment of serum levels of asymmetric dimethylarginine, symmetric dimethylarginine and l-arginine in coronary artery disease

Biomarkers

Volumn 15, Issue 8, 2010, Pages 746-752

  Gad, Mohamed Z ^a   Hassanein, Sally I ^a   Abdel Maksoud, Sahar M ^a   Shaban, Gamal M ^b   Abou Aisha, Khaled ^a   Elgabarty, Hossam A ^a  

^a German University in Cairo   (Egypt)

^b NATIONAL HEART INSTITUTE   (Egypt)

Author keywords

ADMA; Coronary artery disease; DDAH2 gene polymorphism; Egyptians; l arginine; SDMA

Indexed keywords

6 N,N' DIMETHYLARGININE; ARGININE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIMETHYLARGININASE; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 2; N(G),N(G) DIMETHYLARGININE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AMIDOHYDROLASES; ARGININE; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 78649231847     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2010.519784     Document Type: Article

References (30)

1. Afonina I, Zivarts M, Kutyavin I, Lukhtanov E, Gamper H, Meyer RB. (1997). Efficient priming of PCR with short oligonucleotides conjugated to a minor groove binder. Nucleic Acids Res 25:2657-60.
2. Birdsey GM, Leiper JM, Vallance P. (2000). Intracellular localization of dimethylarginine dimethylaminohydrolase overexpressed in an endothelial cell line. Acta Physiol Scand 168:73-9.
3. Boger RH. (2003). The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 59:824-33.
4. Boger RH. (2004). Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the 'L-Arginine Paradox' and acts as a novel cardiovascular risk factor. J Nutr 134:2842S-7S.
5. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, Tsao PS, Kimoto M, Vallance P, Patterson AJ, Cooke JP. (2003). Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 108:3042-7. (Pubitemid 37553576)
6. El-Mesallamy H, Abdel Hamid SG, Gad MZ. (2008). Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: improvements by L-arginine intake. Kidney Blood Press Res 31:189-95.
7. Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H. (1994). Nitric oxide synthase isozymes. Characterization, purification, molecular cloning and functions. Hypertension 23:1121-31.
8. Jonasson TF, Hedner T, Hultberg B, Ohlin H. (2003). Hyperhomocysteinemia is not associated with increased levels of asymmetric dimethylarginine in patients with ischemic heart disease. Eur J Clin Invest 33:543-9.
9. Jones LC, Tran CTL, Leiper JM, Hingorani AD, Vallance P. (2003). Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun 310:836-43.
10. Jones L, Hingorani AD. (2005). Genetic regulation of endothelial function. Heart 91:1275-7.
11. Korandji C, Zeller M, Guilland JC, Vergely C, Sicard P, Duvillard L, Gambert P, Moreau D, Cottin Y, Rochette L. (2007). Asymmetric dimethylarginine (ADMA) and hyperhomocysteinemia in patients with acute myocardial infarction. Clin Biochem 40:66-72.
12. Kutyavin IV, Lukhtano EA, Gamper HB, Meyer RB. (1997). Oligonucleotides with conjugated dihydropyrroloindole tripeptides: base composition and backbone effects on hybridization. Nucleic Acids Res 25:3718-23.
13. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P. (1999) Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deaminases. Biochem J 343:209-14.
14. Lu R, Xiong Y, He P. (2007). Dimethylarginine dimethylaminohydrolase-2 overexpression improves impaired nitric oxide synthesis of endothelial cell induced by glycated protein. Nitric Oxide 16:94-103.
15. Maas R, Erdmann J, Lüneburg N, Stritzke J, Schwedhelm E, Meisinger C, Peters A, Weil J, Schunkert H, Böger RH, Lieb W. (2009). Polymorphisms in the promoter region of the dimethylarginine dimethylaminohydrolase 2 gene are associated with prevalence of hypertension. Pharmacol Res 60:488-93.
16. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. (1996). Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 11:2449-52.
17. Meinitzer A, Puchinger M, Winklhofer-Roob BM, Rock E, Ribalta J, Roob JM, Sundl I, Halwachs-Baumann G, März W. (2007). Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. Clin Chim Acta 384:141-8.
18. Murray-Rust J, Leiper J, McAlister M, Phelan J, Tilley S, Santa Maria J, Vallance P, McDonald N. (2001). Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 8:679-83.
19. O'Dwyer MJ, Dempsey F, Crowley V, Dermot P, Kelleher DP, Ross McManus R, Ryan T. (2006). Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study. Crit Care 10: R139.
20. Palm F, Onozato ML, Luo Z, Wilcox CS. (2007). Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 293: H3227-45.
21. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, Schmidt-Lucke C, Kusus M, Maas R, Schwedhelm E, Strödter D, Simon BC, Mügge A, Daniel WG, Tillmanns H, Maisch B, Streichert T, Böger RH. (2006). Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 152:493. e1-e8.
22. Shwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Böger RH. (2005). Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 51:1268-71.
23. Shwedhelm E, Maas R, Tan-Andresen J, Schulze F, Ulrich Riederer U, Böger RH. (2007). High-throughput liquid chromatographictandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 851:211-19.
24. Tran CTL, Fox MF, Vallance P, Leiper JH. (2000). Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics 68:101-5.
25. Tran CT, Leiper JM, Vallance P. (2003). The DDAH/ADMA/NOS pathway. Atheroscler Suppl 4:33-40.
26. Vallance P, Leone A, Calver A, Collier J, Moncada S. (1992a). Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 339:572-5.
27. Vallance P, Leone A, Calver A, Collier J, Moncada S. (1992b). Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 20: S60-2.
28. Wang D, Gill PS, Chabrashvili T, Onozato ML, Raggio J, Mendonca M, Dennehy K, Li M, Modlinger P, Leiper J, Vallance P, Adler O, Leone A, Tojo A, Welch WJ, Wilcox CS. (2007). Isoform-specific regulation by N (G), N (G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res 101:627-5.
29. Wang J, Sim A, Wang X, Salonikas C, Naidoo D, Wilcken D. (2005). Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 184:383-8.
30. Wong VW, McLean M, Boyages SC, Cheung NW. (2004). C-reactive protein levels following acute myocardial infarction: effect of insulin infusion and tight glycemic control. Diabetes Care 27:2971-3.